Background and Purpose-Hypertension promotes carotid intima-media thickening. We reviewed the randomized controlled trials that evaluated the effects of an antihypertensive drug versus placebo or another antihypertensive agent of a different class on carotid intima-media thickness. Methods-We searched the PubMed and the Web of Science databases for randomized clinical trials, published in English before 2005, and included 22 trials. Results-In 8 trials including 3329 patients with diabetes or coronary heart disease, antihypertensive treatment initiated with an angiotensin-converting enzyme (ACE) inhibitor, a ␤-blocker, or a calcium-channel blocker (CCB), compared with placebo or no-treatment, reduced the rate of intima-media thickening by 7 m/year (Pϭ0.01). In 9 trials including 4564 hypertensive patients, CCBs, ACE inhibitors, an angiotensin II receptor blocker or an ␣-blocker, compared with diuretics or ␤-blockers, in the presence of similar blood pressure reductions, decreased intima-media thickening by 3 m/year (Pϭ0.03). The overall beneficial effect of the newer over older drugs was largely attributable to the decrease of intima-media thickening by 5 m/year (Pϭ0.007) in 4 trials of CCBs involving 3619 patients. In 5 trials including 287 patients with hypertension or diabetes, CCBs compared with ACE inhibitors did not differentially affect blood pressure, but attenuated intima-media thickening by 23 m/year (Pϭ0.02). The treatment induced changes in carotid intima-media thickness correlated with the changes in lumen diameter (Pϭ0.02), but not with the differences in achieved blood pressure (PϾ0.53). Conclusions-CCBs reduce carotid intima-media thickening. This mechanism might contribute to their superior protection against stroke.
I ntima-media thickness (IMT) in the carotid arteries can be measured by using high-resolution ultrasonography. Hypertension is a major risk factor for carotid intima-media thickening. Antihypertensive treatment prevents stroke and coronary heart disease. Several recent trials tested the effects of antihypertensive drugs on carotid IMT. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In the present meta-analysis, we investigated whether antihypertensive treatment reduced carotid IMT, whether new antihypertensive drugs were more effective than old agents in the prevention of carotid intima-media thickening, and whether angiotensin-converting enzyme (ACE) inhibitors and calcium-channel blockers (CCB) were equally effective in this regard. We also studied the relevance of using IMT as an intermediate outcome measure for the prevention of mortality and cardiovascular events.
Methods

Acquisition and Selection of Trials
We searched the PubMed and the Web of Science citation databases for randomized controlled trials, published in English before August 2005, using as key terms "IMT," "blood pressure (BP)," and "randomized clinical trial. " We identified 24 trials, published between 1996 and 2005. We excluded 1 trial because the follow-up time duration was only 2 months 23 and 1 study because out of the 57 patients randomized to quinapril or losartan, 14 crossed over and were not analyzed. 24 According to the study design, we classified the remaining 22 trials into 3 groups: 8 trials compared antihypertensive drugs with placebo 2, 3, [5] [6] [7] 19 or no-treatment, 1,4 9 trials compared new with old drug classes, 8 -14,20,22 and 5 trials compared ACE inhibitors and CCBs. [15] [16] [17] [18] 21 
Data Extraction
We based our analysis on the summary statistics reported in the literature. For carotid IMT, we extracted for the experimental and control groups separately means and standard deviations at baseline and during follow-up and if available in the published report also changes over time. Within each trial, the control group consisted of patients left untreated 1, 4 or allocated placebo, 2, 3, [5] [6] [7] 19 the patients randomized to old drug classes, 8 -14,20,22 or the patients who received ACE inhibitors in trials comparing these agents with CCBs. [15] [16] [17] [18] 21 The number of patients by randomization group was not reported in the IMT substudy of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). 7 
Statistical Analysis
For each comparison within each trial, we calculated the absolute difference in the mean changes over time in carotid IMT (m per year) between the experimental and control groups, and computed the standard error (SE) of the difference as described previously. 25 The pooled effect for each grouping of trials was derived from the point estimate for each separate trial weighted by the inverse of the variance (1/SE 2 ). Heterogeneity of effect sizes was tested across trials using the 2 test. If trials were homogeneous (PϽ0.10), a fixed-effects model was used to calculate pooled effect sizes. Otherwise, a random-effects model was applied. The funnel plot technique was used to evaluate publication bias. 25 The effect sizes of carotid IMT were plotted against the sample size of the 22 studies.
We performed a meta-regression analysis to explore whether the effects of antihypertensive drugs on carotid IMT were mediated by effects on BP or lumen diameter. We correlated the differences in carotid IMT between experimental and control treatment with the corresponding differences in BP and lumen diameter. Net treatment SBP/DBP indicates systolic/diastolic blood pressure; CBIMmax, mean maximum IMT of the common carotid arteries, bifurcations and internal carotid arteries; CM, mean IMT of the common carotid arteries; CBMmax, mean maximum IMT of the common carotid arteries and bifurcations; PR, progression rate; HCTZ, hydrochlorothiazide; HCTZ/A, hydrochlorothiazide/amiloride; CCB, calcium-channel blocker; SR, slow release; GITS, gastrointestinal therapeutic system. See figure legends and text for trial acronym expansions.
*In VHAS, 9 the study medication was administered in a double-blind fashion during the initial 6 months and thereafter in an open way; †possible association with pravastatin (40 mg daily) 19, 20 or fluvastatin (40 mg daily) 5 in a 2ϫ2 factorial design.
effects on BP and lumen diameter were determined by subtracting the mean change in the experimental group from the corresponding mean change in the control group. We ran statistical analyses using the SAS package, version 8.1 (SAS Institute). For mortality and cardiovascular events, we determined the relative benefit or risk of experimental versus control treatment from the odds ratios in stratified 2ϫ2 contingency tables. We used StatXact for Windows (CYTEL Software Corp), version 4.0, to check the homogeneity of the odds ratios by Zelen test and to compute exact 95% CI.
Results
Characteristics of Trials and Patients
Our analysis included 22 studies and 9138 subjects, of whom 8449 (92%) had been randomized in 17 double-blind trials and 689 (8%) in 5 studies with an open design ( Table 1) . In 15 trials, 2, 3, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] 16, 19, 21 the investigators excluded from analysis a proportion of the randomized patients (Ϸ10%) who had incomplete data collection at randomization or during follow-up. Participants in 15 trials 1-4,6,7,9 -13,17-19,21,22 had a broad range of carotid IMT at baseline, whereas the other studies exclusively recruited patients with 5, 8, 20 or without 14 -16 plaques according to various definitions. In all 8 -14,16 -18,20 -22 but 1 15 of the actively-controlled studies, the participants had to have systolic or diastolic hypertension. During follow-up, other antihypertensive drugs could be added to the randomized treatment to reach the target of BP.
In all trials, the major characteristics of the patients at baseline were similar between study groups. The mean age of the study subjects ranged from 49 17, 18 to 68 15 years (Table 2 ). One trial included only patients with hypercholesterolemia. 6 The mean BPs at entry ranged from 129 7 to 175 21 mm Hg systolic and from 76 3, 4, 19 to 104 17 mm Hg diastolic. Mean follow-up duration was from 0.5 15-17 to 4.7 2 years.
Ultrasound Examination
In addition to the baseline measurement, carotid IMT was measured during follow-up once in 5 trials, 1, [15] [16] [17] 19 twice in 8 trials 2-5,12-14,21 and 3 times or more frequently in 9 trials (Table 3) . 6 -11,18,20,22 Carotid IMT was measured at both sides in 16 studies, 1-4,7-9,11,14 -18,20 -22 only at the right 5, 6, 10, 12 or left 13, 19 side in 6 studies, at both the near and far arterial walls in 7 studies, 1, 3, 4, 7, 8, 20, 22 or only at far wall in 15 trials. 2,5,9 -19,21 Mean maximum IMT of multiple carotid segments, the mean of several random measurements, and the mean of the measurements over 1 carotid segment were taken as outcomes in 8, 1,3,7-9,11,20,21 9, 4,12-19 and 5 trials, 2,5,6,10,22 respectively.
Antihypertensive Drugs Versus Placebo or No-Treatment
Altogether, the 8 trials comparing active treatment with placebo or no-treatment included 3329 subjects ( Figure 1 ). and Roman, 13 in which only the characteristics of analyzed patients were given; †positive values indicate tighter blood pressure control on experimental treatment; ‡numbers are the percentage of patients with carotid plaques. The threshold intima-media thickness for diagnosis of plaques is given between parentheses; §values are mean duration of follow-up except for SECURE, 3 in which only median follow-up was reported.
Active antihypertensive treatment consisted of an ACE inhibitor in 5 trials (nϭ2090), [1] [2] [3] [4] 19 a ␤-blocker in 2 trials (nϭ862) 5, 6 and a CCB in 1 trial (nϭ377; Table 1 ). 7 The weighted mean decrease in systolic pressure across the 8 trials was 6.4 mm Hg (95% CI, 2.2 to 10.5; Pϭ0.003).
Mean IMT at baseline ranged from 691 1 to 1259 m. 7 Across the 8 trials, we found significant heterogeneity mainly attributable to the large treatment effect in the Migdalis trial (Pϭ0.001). 1 A random-effects model showed that active antihypertensive treatment significantly reduced the yearly increase in carotid IMT by 7 m (95% CI, Ϫ14 to Ϫ2; Pϭ0.01). The results of the Migdalis trial 1 also produced significant heterogeneity in the 5 ACE inhibitor trials (Pϭ0.003). [1] [2] [3] [4] 19 The pooled effect size based on a random-effects model was similar to that in all trials, but did not reach statistical significance (Pϭ0.07). The combined results of the ␤-blocker trials 5, 6 were not statistically significant with borderline significant heterogeneity among individual trials (Pϭ0.05).
New Drugs Versus Old Drugs
Among the 9 trials comparing new with old drug classes, the new antihypertensive drug was a CCB in 4 trials (nϭ3619), 8 -11 an ACE inhibitor in 3 trials (nϭ640), 12, 13, 20 an angiotensin II receptor blocker in 1 trial (nϭ225) 14 and an ␣-blocker in 1 trial *The longitudinal images were used in most studies. Several studies also captured transversal images; †a fixed section of the common carotid artery was used to measure IMT; ‡the No. of arterial segments used for the calculation of mean IMT or mean maximum IMT is given in the parentheses; §the side (left or right) with greater mean IMT was chosen. In Koshiyama's trial, 15 the investigators took the mean of the maximum IMT and 2 readings of sites, respectively, 1 cm downwards and 1 cm upwards from the site of maximum IMT.
(nϭ80; Table 1 ). 22 Sample sizes varied from 50 13 to 2035 patients (Figure 2 ). 11 The weighted mean decrease in systolic pressure across the 9 trials was 1.1 mm Hg (95% CI, Ϫ2.5 to 0.3; Pϭ0.11).
Mean IMT at baseline ranged from 594 12 to 1410 m. 22 There was no heterogeneity across these trials (PՆ0.19). Compared with old drug classes, new hypertensive drugs significantly reduced the yearly increase in carotid IMT by 3 m (95% CI, Ϫ5 to Ϫ0.3; Pϭ0.01). This result mainly reflected the effect of CCBs 8 -11 because overall ACE inhibitors were not different from old drug classes (Pϭ0.19). 12, 13, 20 
CCBs Versus ACE Inhibitors
A total of 287 patients were included in 5 trials comparing ACE inhibitors with CCBs (Table 1) . [15] [16] [17] [18] 21 The number of patients ranged from 22 15 to 126. 21 The weighted mean decrease in systolic pressure across the 5 trials was Ϫ0.1 mm Hg (95% CI, Ϫ3.5 to 3.4; Pϭ0.97). 20 ; LAARS, the Losartan vascular Regression Study 14 ; DAPHNE, the Doxazosin Atherosclerosis Progression study in Hypertensives in the Netherlands. 22 Mean IMT at baseline ranged from 702 16 to 1038 m (Figure 3) . 21 No heterogeneity was noticed across the 5 trials (Pϭ0.34). Compared with ACE inhibitors, CCBs significantly reduced the yearly increase in carotid IMT by 23 m (95% CI, Ϫ42 to Ϫ4; Pϭ0.02).
Meta-Regression Analysis
The BP difference during follow-up did not predict the treatment-induced difference in the yearly changes of carotid IMT (systolic, nϭ21; rϭ0.13; Pϭ0.57 and diastolic, nϭ22; rϭ0. 16; Pϭ0.49) . However, the treatment-induced differences in the yearly changes of carotid IMT correlated weakly and inversely with the differences in lumen diameter of the common carotid artery during follow-up (nϭ12; rϭϪ0.49; Pϭ0.10; Figure 4 ). This correlation became significant after further adjustment for mean systolic and diastolic pressures at entry (rϭϪ0.73; Pϭ0.02).
Evaluation of Publication Bias
The funnel plot showed a gap, indicating that few small studies with negative results had been published ( Figure 5 ).
Cardiovascular Morbidity and Mortality
Five placebo-controlled trials 2,3,5,7,19,26 and 4 trials evaluating CCBs 8, 9, 11 or an ACE inhibitor 20 versus diuretics or a ␤-blocker reported morbidity and mortality results (Table 4) . Because the trials were inadequately powered for hard outcomes, only the odds ratio for all fatal and nonfatal cardiovascular events in trials comparing active treatment with placebo reached statistical significance (Pϭ0.007).
Discussion
The main finding of our meta-analysis was that treatment with BP-lowering drugs in high-risk patients with diabetes mellitus or coronary heart disease, irrespective of their background treatment, slightly reduced the progression of arterial disease as reflected by carotid intima-media thickening. Furthermore, in the actively-controlled trials CCBs reduced the progression of carotid intima-media thickening more than diuretics, ␤-blockers or ACE inhibitors. The observed reductions in carotid IMT, though small, approximate to the mean yearly progression of carotid intimamedia thickening in middle-aged and older adults. 27 Among the trials which compared antihypertensive drug treatment with placebo or no-treatment, the point estimates for all 3 drug classes favored antihypertensive treatment. The Migdalis trial reported large decreases in BP (22/12 mm Hg) and IMT (73 m/year), but is difficult to interpret because of its open design. 1 BP on randomized treatment might also explain the divergent results in 2 double-blind ␤-blocker trials. 5, 6 Metoprolol compared with placebo lowered systolic pressure on average by 1 mm Hg in the ␤-Blockers Cholesterol-lowering Asymptomatic Plaque Study (BCAPS) 5 and 3 mm Hg in the Effect of Long-term treatment of metoprolol CR/XL on surrogate Variables for Atherosclerotic disease (ELVA) study. 6 A significant effect on the rate of progression of carotid intima-media thickening was only observed in ELVA. 6 Patient characteristics, in particular the presence of diabetes mellitus, may account for some of the differences among the trials comparing ACE inhibitors with placebo or no-treatment. [1] [2] [3] [4] 19 In keeping with Fleckenstein's animal experiments, 28 several trials were mounted to test the hypothesis that calciumchannel blockade might be effective in slowing the progression of carotid atherosclerosis. Compared with no-treatment, the effect size tended to be larger in the PREVENT trial 7 than that in trials that tested ACE inhibitors [1] [2] [3] [4] 19 or ␤-blockers. 5, 6 In the actively controlled trials, CCBs reduced carotid IMT more than diuretics, 8 -10 a ␤-blocker 11 or ACE inhibitors. [15] [16] [17] [18] 21 In successive quantitative overviews, 29 we and other investigators demonstrated that CCBs compared with older drugs, including diuretics, ␤-blockers and their combination, and compared with ACE inhibitors, provided superior protection against stroke. Furthermore, using meta-regression, we additionally demonstrated that in hypertensive and high-risk patients BP-lowering rather than ancillary drug properties explained most of the cardiovascular protection conferred by antihypertensive drugs, but also that CCBs, independent of their BP-lowering activity, might have a small additional beneficial effect in the prevention of stroke. 28 Our current meta-analysis highlights one possible mechanism contributing to the differential effects of antihypertensive drugs on stroke prevention: that is, their influence on the progression of arterial disease at the level of the carotid arteries.
Differences in the progression of carotid IMT might be attributable to either functional or structural changes in the vessel wall, or both. However, it is difficult to differentiate these 2 mechanisms. Our current meta-regression analysis suggests that the treatment-induced differences in carotid IMT might at least in part be attributed to the corresponding differences in changes of lumen diameter. IMT is inversely related to lumen diameter. The reduction in carotid IMT in the patients treated with a CCB might therefore be attributable to a functional decrease by its vasodilatory effect and not necessarily to a structural decrease in intima-media crosssectional area. This hypothesis is also supported by the observation of a larger effect in short-term studies [15] [16] [17] [18] than in long-term trials. [7] [8] [9] [10] [11] Therefore, the clinical relevance of changes in carotid IMT as an intermediate outcome measure has to be further studied in trials with mortality and morbidity as end points.
In conclusion, compared with no-treatment, diuretics/␤-blockers or ACE inhibitors, CCBs attenuate the rate of progression of carotid intima-media thickening. Whether these findings are attributable to functional changes through vasodilation without a structural decrease in cross-sectional area and whether these findings have implications for the long-term prevention of cardiovascular complications such as stroke, remain to be proven. In the prevention of carotid intima-media thickening, CCBs are more effective than ACE inhibitors, which in turn are more effective than placebo or no-treatment, but not more active than diuretics/␤-blockers.
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